Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, dose- range finding, 12-week, double-blind, randomized, parallel group study to evaluate safety and efficacy of GRC 27864 in patients with moderate osteoarthritis pain

Trial Profile

A Phase 2, dose- range finding, 12-week, double-blind, randomized, parallel group study to evaluate safety and efficacy of GRC 27864 in patients with moderate osteoarthritis pain

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2018

At a glance

  • Drugs GRC 27864 (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals Ltd
  • Most Recent Events

    • 26 Jun 2018 Planned End Date changed to 25 Mar 2019.
    • 18 Jan 2018 New trial record
    • 15 Jan 2018 According to a Glenmark Pharmaceuticals media release, the Directorate General of Health Services, Central Drugs Standard Control Organization (CDSCO), Government of India has granted permission to conduct this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top